Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HIV/AIDS

Cleavage and polyadenylation specific factor 6 (CPSF6); cyclophilin A
(CYPA; PPIA)

Cell culture studies suggest blocking interaction between HIV capsid protein and host factors CPSF6 or CYPA could help prevent viral replication. In primary human monocyte-derived macrophages, depletion of CPSF6 or mutation to prevent interaction between the capsid and CPSF6 or CYPA blocked HIV-1 replication and triggered innate immune sensors. In the cells, blocking capsid-host factor interaction using cyclosporine or its derivatives suppressed HIV infection. Next steps include understanding the molecular details of the mechanism of action of cyclosporine and its derivatives as well as the mechanism of the antiviral response.

SciBX 6(48); doi:10.1038/scibx.2013.1392
Published online Dec. 19, 2013

Patent application filed covering composition of matter of a series of compounds; available for licensing through UCL Business plc
Contact: Abigail Watts, UCL Business plc, London, U.K.
e-mail:
a.watts@uclb.com

Rasaiyaah, J. et al. Nature;
published online Nov. 6, 2013;
doi:10.1038/nature12769
Contact: Greg J. Towers, University College London, London, U.K.
e-mail:
g.towers@ucl.ac.uk
Contact: Mahdad Noursadeghi,
same affiliation as above
e-mail:
m.noursadeghi@ucl.ac.uk